- Free from Publisher DM Kendall, MC Riddle, J Rosenstock, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg),
−0.6 ± 0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs.
placebo), yielding placebo-adjusted reductions of −1.0% (10 μg) and ... Cited by 543 - Related articles - All 11 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control
(defined as hemoglobin A1c level ranging from 7.0% to 10.0%) despite combination
metformin and sulfonylurea therapy. Intervention: Exenatide, 10 g twice ... Cited by 330 - Related articles - BL Direct - All 7 versions
- ►endojournals.org PL Brubaker, DJ Drucker - Endocrinology, 2004 - Endocrine Soc Gut peptides exert diverse effects regulating satiety, gastrointestinal motility
and acid secretion, epithelial integrity, and both nutrient absorption and
disposal. These actions are initiated by activation of specific G protein- ... Cited by 216 - Related articles - BL Direct - All 7 versions
- ►endojournals.org DE Cummings, J Overduin, KE Foster- … - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc Obesity is now a global pandemic that continues to accelerate despite the often
Herculean efforts by afflicted individuals to lose weight. These efforts are
thwarted by a physiological system that regulates body weight in a manner ... Cited by 156 - Related articles - BL Direct - All 6 versions
MA Nauck, S Duran, D Kim, D Johns, J … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority
trial was to compare the safety and efficacy of exenatide (an incretin mimetic)
with that of biphasic insulin aspart. Materials and methods Patients on ... Cited by 134 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org D Kim, L MacConell, D Zhuang, PA Kothare, … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—From baseline to week 15, exenatide LAR reduced mean ± SE A1C by
−1.4 ± 0.3% (0.8 mg) and −1.7 ± 0.3% (2.0 mg), compared with +0.4 ± 0.3%
with placebo LAR (P < 0.0001 for both). A1C of ≤7% was achieved by 36 and ... Cited by 128 - Related articles - BL Direct - All 5 versions
- ►annals.org [PDF] B Zinman, BJ Hoogwerf, S Duran Garcia, DR … - Annals of internal medicine, 2007 - Am Coll Physicians Background: Exenatide therapy is effective in combination with metformin or
sulfonylureas for treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are
commonly used, but the efficacy of exenatide with a TZD has not been reported. Cited by 119 - Related articles - BL Direct - All 5 versions
GA Herman, C Stevens, K Van Dyck, A … - Clinical Pharmacology & Therapeutics, 2005 - nature.com Background: Sitagliptin (MK-0431 [(2R)-4-oxo-4-(3-[trifluoromethyl]-5,6-dihydro[
1,2,4]triazolo[4,3-a]pyrazin-7[8H]-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine])
is an orally active, potent, and selective inhibitor of dipeptidyl ... Cited by 115 - Related articles - All 6 versions
- ►endojournals.org DJ Drucker - Endocrinology, 2003 - Endocrine Soc Studies of the natural history of type 2 diabetes inform us that a progressive
decline in ß-cell function is common in diabetic patients independent of the
method of treatment (2). Hence, new approaches are clearly needed that not ... Cited by 101 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org LL Baggio, Q Huang, TJ Brown, DJ Drucker - Diabetes, 2004 - Am Diabetes Assoc Peptide hormones exert unique actions via specific G protein–coupled
receptors; however, the therapeutic potential of regulatory peptides is
frequently compromised by rapid enzymatic inactivation and clearance from ... Cited by 94 - Related articles - BL Direct - All 11 versions
